In fact, emerging interest in the focused targeting of YKL40 led to the development of a YKL40-neutralising antibody, which abrogated tumour angiogenesis and progression of the glioblastoma cells in vitro and in vivo using animal models (Faibish et al. 2011). Here, CHI3L1 is linked to glioblastoma.